Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Cash (2016 - 2025)

CorMedix's Change in Cash history spans 13 years, with the latest figure at $96.3 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 1695.79% year-over-year to $96.3 million; the TTM value through Dec 2025 reached $105.1 million, up 3525.79%, while the annual FY2025 figure was $105.1 million, 3525.79% up from the prior year.
  • Change in Cash for Q4 2025 was $96.3 million at CorMedix, up from -$109.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $96.3 million in Q4 2025 and bottomed at -$109.9 million in Q3 2025.
  • The 5-year median for Change in Cash is -$3.1 million (2021), against an average of $5.0 million.
  • The largest YoY upside for Change in Cash was 1695.79% in 2025 against a maximum downside of 1729.56% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$13.0 million in 2021, then surged by 99.27% to -$95334.0 in 2022, then tumbled by 18653.02% to -$17.9 million in 2023, then surged by 130.01% to $5.4 million in 2024, then soared by 1695.79% to $96.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Change in Cash are $96.3 million (Q4 2025), -$109.9 million (Q3 2025), and $93.0 million (Q2 2025).